levodopa has been researched along with istradefylline in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.76) | 18.2507 |
| 2000's | 14 (33.33) | 29.6817 |
| 2010's | 14 (33.33) | 24.3611 |
| 2020's | 12 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Beauchamp, DA; Boulet, J; Branum, S; Bullington, JL; Chakravarty, D; Damon, S; Davis, S; Demarest, K; Hall, D; Hansen, K; Heintzelman, GR; Jackson, PF; Li, X; Osborne, MC; Palmer, D; Rassnick, S; Reyes, M; Rhodes, K; Rupert, KC; Russell, R; Shook, BC; Tang, Y; Wells, KM; Westover, L; Youells, S | 1 |
| Gaba, S; Gupta, GD; Monga, V; Patel, R; Saini, A; Singh, G | 1 |
| Bédard, PJ; Grégoire, L; Grondin, R; Hadj Tahar, A; Kase, H; Mori, A | 1 |
| Ichikawa, S; Kitamura, S; Kuwana, Y; Nakamura, J; Shiozaki, S; Yamada, K | 1 |
| Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA | 1 |
| Koga, K; Kurokawa, M; Kuwana, Y; Nakamura, J; Ochi, M | 1 |
| Cenci, MA; Lundblad, M; Vaudano, E | 1 |
| Bara-Jimenez, W; Bibbiani, F; Chase, TN; Dimitrova, T; Favit, A; Gillespie, M; Morris, MJ; Mouradian, MM; Sherzai, A | 1 |
| Hauser, RA; Hubble, JP; Truong, DD | 1 |
| Bibbiani, F; Castagnoli, N; Chase, TN; Chen, JF; Oh, JD; Petzer, JP; Schwarzschild, MA | 1 |
| Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L | 1 |
| Aoyama, S; Bedard, P; Borrelli, E; Chase, TN; Hauser, RA; Ichimura, M; Ikeda, K; Ishii, A; Jenner, P; Kanda, T; Kase, H; Koga, K; Koike, N; Kurokawa, M; Kuwana, Y; Mori, A; Nakamura, J; Nonaka, H; Ochi, M; Richardson, PJ; Saki, M; Shimada, J; Shindou, T; Shiozaki, S; Suzuki, F; Takeda, M; Yanagawa, K | 1 |
| Bara-Jimenez, W; Bibbiani, F; Chase, TN; Dimitrova, T; Oh-Lee, JD | 1 |
| Waters, C | 1 |
| Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A | 1 |
| Morelli, M; Pinna, A; Simola, N; Wardas, J | 1 |
| Bastia, E; Benn, CL; Cha, JH; Chen, JF; Peterson, TS; Schwarzschild, MA; Xiao, D; Xu, YH | 1 |
| Ballerini, R; Hauser, RA; Mori, A; Roberts, JW; Shulman, LM; Sussman, NM; Trugman, JM | 1 |
| Auguet, M; Chabrier, PE; Charnet, C; Cornet, S; Roubert, V; Spinnewyn, B | 1 |
| Chen, W; Gu, S; Wang, H; Wei, H | 1 |
| Müller, T | 2 |
| Merello, M; Perez-Lloret, S | 1 |
| Jenner, P; Kanda, T; Kawai-Uchida, M; Mori, A; Tashiro, T; Uchida, S | 1 |
| Chen, L; Li, J; Lin, P; Ran, H; Wang, C; Wang, G; Wang, Y; Zhu, C | 1 |
| Liang, G; Tao, Y | 1 |
| Jenner, P; Kanda, T; Kawai-Uchida, M; Mori, A; Okita, E; Soshiroda, K; Uchida, S | 2 |
| Downey, P; Michel, A; Nicolas, JM; Scheller, D | 1 |
| Li, ZJ; Wu, Q; Yi, CJ | 1 |
| Antonini, A; Vorovenci, RJ | 1 |
| Bezard, E; Camus, SM; Ko, WKD; Li, Q; McGuire, S; Pioli, EY; Yang, J | 1 |
| Paton, DM | 1 |
| Aradi, SD; Hauser, RA; LeWitt, PA; Rascol, O | 1 |
| Fernandez, H; Hattori, N; Hauser, RA; Isaacson, SH; LeWitt, P; Li, J; Mochizuki, H; Mori, A; Nakajima, Y; Rascol, O; Ristuccia, R; Stocchi, F | 1 |
| Chiu, SW; Hattori, N; Kashihara, K; Maeda, T; Nomoto, M; Saiki, H; Shimo, Y; Tsuboi, Y; Watanabe, H; Yamaguchi, T | 1 |
| Ito, H; Kajimoto, Y; Koh, J; Mori, A; Shimokawa, T; Takahashi, M; Takeshima, T; Yamashita, H | 1 |
| Chen, B; Feng, ST; Hu, D; Wang, XL; Wang, ZZ; Zhang, Y | 1 |
| Fukae, J; Hatano, T; Hirano, S; Joki, H; Kano, O; Kimura, K; Matsukawa, MK; Mukai, Y; Murakami, H; Nagayama, H; Nishikawa, N; Nomura, K; Ogaki, K; Seki, M; Sengoku, R; Shimura, H; Suzuki, K; Takahashi, K; Tashiro, J; Terashi, H; Tsuboi, Y; Uchiyama, T; Yamamoto, T; Yanagisawa, N; Yoritaka, A; Yoshida, N | 1 |
| Katsuno, M; Komori, S; Nakamura, T; Suzuki, M; Tsuboi, T | 1 |
| Horiguchi, S; Ito, S; Takahashi, M; Tsuji, Y | 1 |
14 review(s) available for levodopa and istradefylline
| Article | Year |
|---|---|
Adenosine receptor antagonists: Recent advances and therapeutic perspective.
Topics: Dose-Response Relationship, Drug; Humans; Molecular Structure; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Structure-Activity Relationship | 2022 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Primates; Purines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine D2 | 2003 |
Translating A2A antagonist KW6002 from animal models to parkinsonian patients.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Humans; Levodopa; Macaca fascicularis; Male; Motor Activity; Neurons; Parkinsonian Disorders; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2003 |
Other pharmacological treatments for motor complications and dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Periodicity; Purinergic P1 Receptor Antagonists; Purines; Selegiline | 2005 |
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Parkinson Disease; Primates; Purines; Receptor, Adenosine A2A | 2005 |
Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Blood-Brain Barrier; Disease Models, Animal; Dopamine Agonists; Dyskinesias; Half-Life; Humans; Levodopa; Parkinson Disease; Purines; Treatment Outcome | 2013 |
Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Levodopa; Parkinson Disease; Purines; Treatment Outcome | 2014 |
Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
Topics: Adenosine A2 Receptor Antagonists; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
Topics: Adenosine A2 Receptor Antagonists; Drug Synergism; Humans; Levodopa; Parkinson Disease; Purines; Randomized Controlled Trials as Topic; Receptor, Adenosine A2A | 2015 |
Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Purines; Receptor, Adenosine A2A | 2020 |
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Double-Blind Method; Dyskinesias; Humans; Levodopa; Parkinson Disease; Purinergic P1 Receptor Antagonists; Purines; Randomized Controlled Trials as Topic; Receptor, Adenosine A2A; Treatment Outcome | 2021 |
Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; Purines; Treatment Outcome | 2022 |
The role of istradefylline in the Parkinson's disease armamentarium.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Purines | 2023 |
5 trial(s) available for levodopa and istradefylline
| Article | Year |
|---|---|
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Purines; Safety; Treatment Outcome | 2003 |
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chronic Disease; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nausea; Parkinson Disease; Purines; Safety; Selegiline; Treatment Outcome | 2003 |
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 2008 |
Clinical efficacy of istradefylline versus rTMS on Parkinson's disease in a randomized clinical trial.
Topics: Aged; China; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Transcranial Magnetic Stimulation; Treatment Outcome | 2015 |
Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
Topics: Adenosine A2 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Humans; Levodopa; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Purines; Randomized Controlled Trials as Topic | 2022 |
23 other study(ies) available for levodopa and istradefylline
| Article | Year |
|---|---|
In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Disease Models, Animal; Female; Indenes; Macaca fascicularis; Male; Mice; Mice, Inbred BALB C; Parkinson Disease; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A | 2010 |
Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Receptor, Adenosine A2A | 1999 |
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Antiparkinson Agents; Antipsychotic Agents; Caffeine; Catalepsy; Dopamine Agents; Hypokinesia; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Phenethylamines; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Reserpine; Theophylline | 1999 |
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Quinpirole; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2000 |
Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Xanthines | 2000 |
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; RNA, Messenger; Treatment Outcome | 2003 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Apomorphine; Denervation; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Sympatholytics | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles | 2003 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome | 2005 |
Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders; Prosencephalon; Purines; Receptor, Adenosine A2A | 2006 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Biological Assay; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Placebos; Purines; Random Allocation; Rats; Reproducibility of Results; Rotation; Sample Size; Single-Blind Method; Sympatholytics | 2011 |
Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Drug Synergism; Dyskinesias; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Purines | 2014 |
The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Callithrix; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Female; Indoles; Levodopa; Male; Motor Activity; Pergolide; Purines; Receptor, Adenosine A2A | 2015 |
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Benzothiazoles; Drug Therapy, Combination; Levodopa; Mass Spectrometry; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Purines; Pyrimidines; Rats; Receptors, N-Methyl-D-Aspartate; Triazoles | 2014 |
The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dopamine Agonists; Drug Therapy, Combination; Female; Indoles; Levodopa; Male; Motor Activity; MPTP Poisoning; Pergolide; Purines | 2015 |
The efficacy of oral adenosine A(2A) antagonist istradefylline for the treatment of moderate to severe Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Humans; Japan; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Purines | 2015 |
An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.
Topics: Adenosine A2 Receptor Antagonists; Animals; Cognition Disorders; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hypokinesia; Levodopa; Macaca fascicularis; Motor Skills Disorders; MPTP Poisoning; Purines; Treatment Outcome | 2016 |
Istradefylline (Nourianz) for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Purines | 2020 |
The challenge of developing adenosine A
Topics: Adenosine; Animals; Antiparkinson Agents; Benzothiazoles; Humans; Levodopa; Parkinson Disease; Purines | 2020 |
Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST).
Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2021 |
Efficacy and safety of istradefylline in patients with Parkinson's disease presenting with postural abnormalities: Results from a multicenter, prospective, and open-label exploratory study in Japan.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Humans; Japan; Levodopa; Parkinson Disease; Prospective Studies; Purines; Quality of Life; Treatment Outcome | 2022 |
[Dyskinesia-hyperpyrexia syndrome triggered by overdose of istradefylline: a case report].
Topics: Aged; Antiparkinson Agents; Drug Overdose; Dyskinesias; Female; Fever; Humans; Levodopa; Parkinson Disease; Purines | 2022 |
Safety and effectiveness of istradefylline as add-on therapy to levodopa in patients with Parkinson's disease: Final report of a post-marketing surveillance study in Japan.
Topics: Adult; Aged; Drug-Related Side Effects and Adverse Reactions; Female; Hallucinations; Humans; Japan; Levodopa; Male; Parkinson Disease; Product Surveillance, Postmarketing; Prospective Studies | 2022 |